Home/Pipeline/Isabl GxT Solid

Isabl GxT Solid

Solid Tumors

UnknownActive

Key Facts

Indication

Solid Tumors

Phase

Unknown

Status

Active

Company

Isabi

About Isabi

Isabl is a private, pre-revenue diagnostics company developing a comprehensive whole-genome and transcriptome sequencing (WGTS) platform for cancer. Its proprietary Isabl GxT technology, which has received FDA Breakthrough Device Designation, aims to replace limited gene panels by analyzing the entire tumor genome and transcriptome to identify all classes of clinically relevant biomarkers from a single biopsy. Spun out from Memorial Sloan Kettering Cancer Center in 2020, the company is backed by notable investors including Two Sigma Ventures and Y Combinator and is preparing for a Research Use Only (RUO) release of its test in 2024 while pursuing clinical partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed